Effects of the dopamine stabilizer, OSU-6162, on brain stimulation reward and on quinpirole-induced changes in reward and locomotion

European Neuropsychopharmacology

Volumn 19, Issue 6, 2009, Pages 416-430

  Benaliouad, Faïza ^a,b   Kapur, Shitij ^c   Natesan, Sridhar ^c   Rompré, Pierre Paul ^a,b  

^a CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Dopamine; Haloperidol; Locomotion; OSU 6162; Quinpirole; Reward

Indexed keywords

3 [3 (METHYLSULFONYL)PHENYL] 1 PROPYLPIPERIDINE; DOPAMINE; HALOPERIDOL; QUINPIROLE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; BRAIN DEPTH STIMULATION; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REWARD;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CONDITIONING, OPERANT; DEEP BRAIN STIMULATION; DOPAMINE AGENTS; HALOPERIDOL; LOCOMOTION; MALE; PIPERIDINES; QUINPIROLE; RATS; RATS, SPRAGUE-DAWLEY; REWARD; SELF ADMINISTRATION; TIME FACTORS;

EID: 67349262381     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2009.01.014     Document Type: Article

References (77)

1. Abercrombie E.D., DeBoer P., and Heeringa M.J. Biochemistry of somatodendritic dopamine release in substantia nigra: an in vivo comparison with striatal dopamine release. Adv. Pharmacol. 42 (1998) 133-136
2. Abraini J.H., Fechtali T., and Rostain J.-C. Pressure reversed extracellular striatal dopamine decrease produced by D1 receptor agonist SKF 38393, and D2 receptor agonist LY 171555, but failed to change the effect of the activation of both D1 and D2 receptors. Neuroscience 50 (1992) 395-402
3. Accili D., Fishburn C.S., Drago J., Steiner H., Lachowicz J.E., Park B.H., Gauda E.B., Lee E.J., Cool M.H., Sibley D.R., Gerfen C.R., Westphal H., and Fuchs S. A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 1945-1949
4. Agid O., Kapur S., and Remington G. Emerging drugs for schizophrenia. Expert Opin. Emerg. Drugs 13 (2008) 479-495
5. Benaliouad F., Kapur S., and Rompre P.P. Blockade of 5-HT2a receptors reduces haloperidol-induced attenuation of reward. Neuropsychopharmacology 32 (2007) 551-561
6. Blanchet P.J., Gomez-Mancilla B., and Bedard P.J. DOPA-induced « peak dose » dyskinesia: clues implicating D2 receptor-mediated mechanisms using dopaminergic agonists in MPTP monkeys. J. Neural Transm., Suppl. 45 (1995) 103-112
7. Bowery B., Rothwell L.A., and Seabrook G.R. Comparison between the pharmacology of dopamine receptors mediating the inhibition of cell firing in rat brain slices through the substantia nigra pars compacta and ventral tegmental area. Br. J. Pharmacol. 112 (1994) 873-880
8. Boye S.M., and Rompre P.P. Effect of pimozide on self-stimulation threshold under a continuous and fixed-interval schedule of reinforcement. Behav. Brain Res. 78 (1996) 243-245
9. Boye S.M., and Rompre P.P. Behavioral evidence of depolarization block of dopamine neurons after chronic treatment with haloperidol and clozapine. J. Neurosci. 20 (2000) 1229-1239
10. Brandt-Christensen M., Andersen M.B., Fink-Jensen A., Werge T., and Gerlach J. The substituted (S)-3-phenylpiperidine (-)-OSU6162 reduces apomorphine- and amphetamine-induced behaviour in Cebus apella monkeys. J. Neural Transm. 113 (2006) 11-19
11. Carlsson M.L., Carlsson A., and Nilsson M. Schizophrenia: from dopamine to glutamate and back. Curr. Med. Chem. 11 (2004) 267-277
12. Carr K.D., Yamamoto N., Omura M., Cabeza de Vaca S., and Krahne L. Effects of the D(3) dopamine receptor antagonist, U99194A, on brain stimulation and d-amphetamine reward, motor activity, and c-fos expression in ad libitum fed and food-restricted rats. Psychopharmacology (Berl) 163 (2002) 76-84
13. Centonze D., Usiello A., Gubellini P., Pisani A., Borrelli E., Bernardi G., and Calabresi P. Dopamine D2 receptor-mediated inhibition of dopaminergic neurons in mice lacking D2L receptors. Neuropsychopharmacology 27 (2002) 723-726
14. Crawley J.N. Attenuation of dark-induced hyperlocomotion by a cholecystokinin antagonist in the nucleus accumbens. Brain Res. 473 (1988) 398-400
15. Dal Toso R., Sommer B., Ewert M., Herb A., Pritchett D.B., Bach A., Shivers B.D., and Seeburg P.H. The dopamine D2 receptor: two molecular forms generated by alternative splicing. EMBO J. 8 (1989) 4025-4034
16. Depoortere R., Perrault G., and Sanger D.J. Behavioural effects in the rat of the putative dopamine D3 receptor agonist 7-OH-DPAT: comparison with quinpirole and apomorphine. Psychopharmacology (Berl) 124 (1996) 231-240
17. Eilam D., and Szechtman H. Biphasic effect of D-2 agonist quinpirole on locomotion and movements. Eur. J. Pharmacol. 161 (1989) 151-157
18. Elmer G.I., Brockington A., Gorelick D.A., Carrol F.I., Rice K.C., Matecka D., Goldberg S.R., and Rothman R.B. Cocaine cross-sensitization to dopamine uptake inhibitors: unique effects of GBR12909. Pharmacol. Biochem. Behav. 53 (1996) 911-918
19. Elmer G.I., Pieper J.O., Levy J., Rubinstein M., Low M.J., Grandy D.K., and Wise R.A. Brain stimulation and morphine reward deficits in dopamine D2 receptor-deficient mice. Psychopharmacology (Berl) 182 (2005) 33-44
20. Fénelon G., Mahieux F., Huon R., and Ziégler M. Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors. Brain 123 (2000) 733-745
21. Flagstad P., Arnt J., and Olsen C.K. Classical as well as novel antipsychotic drugs increase self-stimulation threshold in the rat-similar mechanism of action?. Eur. J. Pharmacol. 544 (2006) 69-76
22. Fouriezos G., and Francis S. Apomorphine and electrical self-stimulation of rat brain. Behav. Brain Res. 52 (1992) 73-80
23. Gallistel C.R., and Freyd G. Quantitative determination of the effects of catecholaminergic agonists and antagonists on the rewarding efficacy of brain stimulation. Pharmacol. Biochem. Behav. 26 (1987) 731-741
24. Galvan A., and Wichmann T. Pathophysiology of parkinsonism. Clin. Neurophysiol. 119 (2008) 1459-1474
25. Goto Y., Otani S., and Grace A.A. The Yin and Yang of dopamine release: a new perspective. Neuropharmacology 53 (2007) 583-587
26. Guiramand J., Montmayeur J.P., Ceraline J., Bhatia M., and Borrelli E. Alternative splicing of the dopamine D2 receptor directs specificity of coupling to G-proteins. J. Biol. Chem. 270 (1995) 7354-7358
27. Hadj Tahar A., Ekesbo A., Gregoire L., Bangassoro E., Svensson K.A., Tedroff J., and Bedard P.J. Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys. Eur. J. Pharmacol. 412 (2001) 247-254
28. Hernandez G., Hamdani S., Rajabi H., Conover K., Stewart J., Arvanitogiannis A., and Shizgal P. Prolonged rewarding stimulation of the rat medial forebrain bundle: neurochemical and behavioral consequences. Behav. Neurosci. 120 (2006) 888-904
29. Hernandez G., Rajabi H., Stewart J., Arvanitogiannis A., and Shizgal P. Dopamine tone increases similarly during predictable and unpredictable administration of rewarding brain stimulation at short inter-train intervals. Behav. Brain Res. 188 (2008) 227-232
30. Hietala J., Syvalahti E., Vuorio K., Rakkolainen V., Bergman J., Haaparanta M., Solin O., Kuoppamaki M., Kirvela O., and Ruotsalainen U. Presynaptic dopamine function in striatum of neuroleptic-naïve schizophrenic patients. Lancet 346 (1995) 1130-1131
31. Horvitz J.C., Williams G., and Joy R. Time-dependent actions of D2 family agonist quinpirole on spontaneous behavior in the rat: dissociation between sniffing and locomotion. Psychopharmacology (Berl) 154 (2001) 350-355
32. Iaccarino C., Samad T.A., Mathis C., Kercret H., Picetti R., and Borrelli E. Control of lactotrop proliferation by dopamine: essential role of signaling through D2 receptors and ERKs. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 14530-14535
33. Kapur S., VanderSpek S.C., Brownlee B.A., and Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J. Pharmacol. Exp. Ther. 305 (2003) 625-631
34. Khan Z.U., Mrzljak L., Gutierrez A., de la Calle A., and Goldman-Rakic P.S. Prominence of the dopamine D2 short isoform in dopaminergic pathways. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 7731-7736
35. Kirk R.E. Experimental design:Procedures for the behavioral sciences (1968), Brookes/Cole, Belmont, USA
36. Koeltzow T.E., Austin J.D., and Vezina P. Behavioral sensitization to quinpirole is not associated with increased nucleus accumbens dopamine overflow. Neuropharmacology 44 (2003) 102-110
37. Koob G.F., and Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 24 (2001) 97-129
38. Lahti R.A., Tamminga C.A., and Carlsson A. Stimulating and inhibitory effects of the dopamine "stabilizer" (-)-OSU6162 on dopamine D(2) receptor function in vitro. J. Neural Transm. 114 (2007) 1143-1146
39. Laruelle M., bi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., McCance E., Rosenblatt W., Fingado C., Zoghbi S.S., Baldwin R.M., Seibyl J.P., Krystal J.H., Charney D.S., and Innis R.B. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 9235-9240
40. Legault M., and Wise R.A. Novelty-evoked elevations of nucleus accumbens dopamine: dependence on impulse flow from the ventral subiculum and glutamatergic neurotransmission in the ventral tegmental area. Eur. J. Neurosci. 13 (2001) 819-828
41. Leith N.J. Effects of apomorphine on self-stimulation responding: does the drug mimic the current?. Brain Res. 277 (1983) 129-136
42. Lindgren N., Usiello A., Goiny M., Haycock J., Erbs E., Greengard P., Hokfelt T., Borrelli E., and Fisone G. Distinct roles of dopamine D2L and D2S receptor isoforms in the regulation of protein phosphorylation at presynaptic and postsynaptic sites. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 4305-4309
43. 11C)DOPA and PET. Biol. Psychiatry 46 (1999) 681-688
44. Liu Y.F., Jakobs K.H., Rasenick M.M., and Albert P.R. G protein specificity in receptor-effector coupling. Analysis of the roles of G0 and Gi2 in GH4C1 pituitary cells. J. Biol. Chem. 269 (1994) 13880-13886
45. Marsden C.A. Dopamine: the rewarding years. Br. J. Pharmacol. 147 Suppl 1 (2006) S136-S144
46. McNamara R.K., Logue A., Stanford K., Xu M., Zhang J., and Richtand N.M. Dose-response analysis of locomotor activity and stereotypy in dopamine D3 receptor mutant mice following acute amphetamine. Synapse 60 (2006) 399-405
47. Miliaressis E., Malette J., and Coulombe D. The effects of pimozide on the reinforcing efficacy of central grey stimulation in the rat. Behav. Brain Res. 21 (1986) 95-100
48. Miliaressis E., Rompre P.P., Laviolette P., Philippe L., and Coulombe D. The curve-shift paradigm in self-stimulation. Physiol. Behav. 37 (1986) 85-91
49. Mundl W.J. A constant-current stimulator. Physiol. Behav. 24 (1980) 991-993
50. Nakajima S., and McKenzie G.M. Reduction of the rewarding effect of brain stimulation by a blockade of dopamine D1 receptor with SCH 23390. Pharmacol. Biochem. Behav. 24 (1986) 919-923
51. Nakajima S., and O'Regan N.B. The effects of dopaminergic agonists and antagonists on the frequency-response function for hypothalamic self-stimulation in the rat. Pharmacol. Biochem. Behav. 39 (1991) 465-468
52. Nakajima S., Liu X., and Lau C.L. Synergistic interaction of D1 and D2 dopamine receptors in the modulation of the reinforcing effect of brain stimulation. Behav. Neurosci. 107 (1993) 161-165
53. Natesan S., Svensson K.A., Reckless G.E., Nobrega J.N., Barlow K.B., Johansson A.M., and Kapur S. The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat. J. Pharmacol. Exp. Ther. 318 (2006) 810-818
54. Obeso J.A., Olanow C.W., and Nutt J.G. Levodopa motor complications in Parkinson's disease. Trends Neurosci. 23 (2000) S2-S7
55. Ouagazzal A.M., and Creese I. Intra-accumbens infusion of D(3) receptor agonists reduces spontaneous and dopamine-induced locomotion. Pharmacol. Biochem. Behav. 67 (2000) 637-645
56. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates. 2nd ed (1986), Academic Press, Sydney
57. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates. 4th ed (1998), Academic Press, San Diego
58. Ranaldi R., and Beninger R.J. The effects of systemic and intracerebral injections of D1 and D2 agonists on brain stimulation reward. Brain Res. 651 (1994) 283-292
59. Rompre P.P. Psychostimulant-like effect of central microinjection of neurotensin on brain stimulation reward. Peptides 16 (1995) 1417-1420
60. Rung J.P., Carlsson A., Markinhuhta K.R., and Carlsson M.L. The dopaminergic stabilizers (-)-OSU6162 and ACR16 reverse (+)-MK-801-induced social withdrawal in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 29 (2005) 833-839
61. Rung J.P., Rung E., Helgeson L., Johansson A.M., Svensson K., Carlsson A., and Carlsson M.L. Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization. J. Neural Transm. 115 (2008) 899-908
62. Seeman P., and Guan H.C. Dopamine partial agonist action of (-)OSU6162 is consistent with dopamine hyperactivity in psychosis. Eur. J. Pharmacol. 557 (2007) 151-153
63. Senogles S.E. The D2 dopamine receptor isoforms signal through distinct Gi alpha proteins to inhibit adenylyl cyclase. A study with site-directed mutant Gi alpha proteins. J. Biol. Chem. 269 (1994) 23120-23127
64. Shilliam C.S., and Heidbreder C.A. Gradient of dopamine responsiveness to dopamine receptor agonists in subregions of the rat nucleus accumbens. Eur. J. Pharmacol. 477 (2003) 113-122
65. Smith J.W., Fetsko L.A., Xu R., and Wang Y. Dopamine D2L receptor knockout mice display deficits in positive and negative reinforcing properties of morphine and in avoidance learning. Neuroscience 113 (2002) 755-765
66. Sokoloff P., Giros B., Martres M.P., Bouthenet M.L., and Schwartz J.C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347 (1990) 146-151
67. Sonesson C., Lin C.H., Hansson L., Waters N., Svensson K., Carlsson A., Smith M.W., and Wikstrom H. Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships. J. Med. Chem. 37 (1994) 2735-2753
68. Usiello A., Baik J.H., Rouge-Pont F., Picetti R., Dierich A., LeMeur M., Piazza P.V., and Borrelli E. Distinct functions of the two isoforms of dopamine D2 receptors. Nature 408 (2000) 199-203
69. Van II H., Banihashemi B., Wilson A.M., Jacobsen K.X., Czesak M., and Albert P.R. Differential signaling of dopamine-D2S and -D2L receptors to inhibit ERK1/2 phosphorylation. J. Neurochem. 102 (2007) 1796-1804
70. Wachtel S.R., Hu X.-T., Galloway M.P., and White F.J. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems. Synapse 4 (1989) 327-346
71. Walters J.T., Bergstrom D.A., Carlson J.H., Chase T.N., and Braun A.R. D1 dopamine receptor activation required for postsynaptic expression of D2 agonist effects. Science 236 (1987) 719-722
72. Wang Y., Xu R., Sasaoka T., Tonegawa S., Kung M.P., and Sankoorikal E.B. Dopamine D2 long receptor-deficient mice display alterations in striatum-dependent functions. J. Neurosci. 20 (2000) 8305-8314
73. Wise R.A. Neurobiology of addiction. Curr. Opin. Neurobiol. 6 (1996) 243-251
74. Wise R.A., and Rompre P.P. Brain dopamine and reward. Annu. Rev. Psychol. 40 (1989) 191-225
75. Xi Z.X., and Gardner E.L. Pharmacological actions of NGB 2904, a selective dopamine D3 receptor antagonist, in animal models of drug addiction. CNS Drug Rev. 13 (2007) 240-259
76. Xu M., Koeltzow T.E., Santiago G.T., Moratalla R., Cooper D.C., Hu X.T., White N.M., Graybiel A.M., White F.J., and Tonegawa S. Dopamine D3 receptor mutant mice exhibit increased behavioral sensitivity to concurrent stimulation of D1 and D2 receptors. Neuron 19 (1997) 837-848
77. Xu R., Hranilovic D., Fetsko L.A., Bucan M., and Wang Y. Dopamine D2S and D2L receptors may differentially contribute to the actions of antipsychotic and psychotic agents in mice. Mol. Psychiatry 7 (2002) 1075-1082